Global Electrocardiographs Market (2021 to 2031) - Featuring Abbott Laboratories, Biotricity and Boston Scientific Among Others

News provided by

Aug 09, 2021, 12:15 ET

DUBLIN, Aug. 9, 2021 /PRNewswire/ -- The "Global Electrocardiographs Market: Focus on Product Type, End User, Region, COVID-19 Impact, Competitive Landscape, and 22 Countries Data - Analysis and Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering.

The Global Electrocardiographs Market is to Reach $9,826.8 Million by 2031.

Key Companies Profiled

Abbott Laboratories, Biotricity, Inc., BIOTRONIK SE & Co. KG, Boston Scientific Corporation, CardioComm Solutions, Inc., Cardioline SpA, Fukuda Denshi Co., Ltd., General Electric Company, Hill-Rom Holdings, Inc., iRhythm Technologies, Inc., Koninklijke Philips N.V., Medtronic plc, Nihon Kohden Corporation, OSI Systems, Inc., Zoll Medical Corporation (Asahi Kasei Corporation)

Who should buy this report?

Electrocardiographs manufacturers (emerging and established)
Established technology companies
Cardiac instruments and Cath lab manufacturers
Healthcare facilities

Key Questions Answered in the Report

What was the impact of the COVID-19 pandemic on the global electrocardiographs market?
What are the key technological trends that influence the global electrocardiographs market? What is their future potential?
Who are the emerging or regional players in the global electrocardiographs market?
What are the legal regulations for electrocardiograph devices across various economies?
How has the patent filing trend influenced the growth of the global electrocardiographs market?
Who are the key players in the global electrocardiographs market?
What are the key synergistic activities employed by the companies operating or entering the global electrocardiographs market?
What are the key drivers and restraints for the global electrocardiographs market?
What are the growth opportunities in the global electrocardiographs market?
Which product type is anticipated to grow with the highest CAGR during the forecast period 2021-2031?
Which geographical region is anticipated to dominate the global electrocardiographs market during the forecast period 2021-2031?

Global Electrocardiographs Overview

An electrocardiograph (ECG) machine records the electrical activity of your heart. The ECG machine detects the electrical signals that make the heart pump blood around body. Conventional devices and emerging devices are two types of electrocardiographs based on product type. Conventional devices can be categorized into resting ECG machines and stress ECG machines. Electrocardiographs are currently dominated by conventional devices. ECG monitoring systems have been created and widely used in the healthcare business for past decades, and as smart supporting technologies have emerged, they have evolved substantially. ECG monitoring devices are now often employed in hospitals, home care settings, outpatient ambulatory settings, and remote settings. Under the conventional devices segment, resting ECG machines and stress ECG machines are included, whereas, under the emerging devices segment, implantable loop recorders, mobile cardiac telemetry, Holter monitors, and cardiac event monitors are included in the report.

The global electrocardiographs market report highlights that the market was valued at $4,394.1 million in 2020 and is expected to reach $9,826.8 million by the end of 2031. The market is expected to grow at a CAGR of 7.8% during the forecast period 2021-2031.

Global Electrocardiographs Market Dynamics

In the global electrocardiographs market, advancements have already occurred and are currently conquering the industry. There is significant potential for these developing and new technologies to promote the total growth of the market with the advent of advanced technologies that can be easily used in ambulatory and home care settings.

Accuracy, precision, timeliness, and authenticity are the four foundations of good laboratory services. In order to improve the analytical difficulties of sample processing, clinical biochemists typically overlook the need for timeliness. Clinicians, on the other hand, usually use timeliness as a benchmark for laboratory performance, which is expressed as the turnaround time (TAT). Short TATs help clinicians diagnose and treat patients as quickly as feasible, as well as discharge patients from emergency departments or hospital in-patient services.

One of the most common concerns with diagnosis is false and incomplete diagnoses. False-negative readings are the most typical issue with ECG. Other symptoms of any underlying heart didorder, such as chest pain, must be considered, and extra testing may be required. Delayed TAT and incomplete/false diagnosis results can have a negative impact on the market.

Modern cardiac imaging, which may include many modalities, is essential to correctly characterize the anatomy and physiology of pediatric and congenital heart disease. Newer imaging modalities, such as cardiac magnetic resonance imaging (CMR) and cardiac computed tomography angiography (CCTA), are increasingly being employed. When it comes to deciding on intervention or surgery for congenital or acquired heart disease, echocardiography and electrocardiography (ECG) are still the gold standards for non-invasive diagnosis. Due to the fast proliferation of medical imaging workstations, companies are working on improving technology and enabling public access to the software.

Company growth at workstations for medical imaging will be driven by rising demand for digital platforms, as well as new medical facilities and advancements in the healthcare business. The global electrocardiographs market is predicted to increase as a result of these improvements in multimodal diagnostic imaging for cardiovascular disorders.

Impact of COVID-19 on Global Electrocardiographs Market

Due to the increased cardiac complications caused by the COVID-19 virus, the overall market for diagnostic electrocardiographs, particularly conventional electrocardiographs, has a positive impact during this phase; however, implantable loop recorders have a minor impact when compared to conventional cardiac monitors due to the high cost of the equipment. Due to the requisite infrastructure not being in place to deal with the overwhelming number of cases in most nations, the impact was greater, particularly in the first months of February and March.

The electrocardiographs (ECG) machine is one of the key instruments for measuring the extent of cardiac involvement in COVID-19 patients and the effect of medications in this scenario due to its wide accessibility, low cost, and ability to be studied remotely.

Key Highlights

According to the global electrocardiographs market report, the conventional devices segment is dominating the market in 2020 when compared to emerging devices segment under the segmentation - by product type. Emerging devices are forecasted to uphold this position in the market and dominate by the end of the forecast period 2021-2031.
In conventional devices segmentation, resting ECG machines are the market leader. During the forecast period 2021-2031, resting ECG is projected to lead the market. Stress ECG is projected to rise at a faster pace than resting ECG machines, with a CAGR of 6.1%.
In emerging devices segmentation, resting implantable loop recorders is the market leader. By the end of the forecast period 2021-2031, mobile cardiac telemetry is projected to lead the market. Mobile cardiac telemetry is projected to rise at a faster pace than implantable loop recorders, with a CAGR of 11.7%.
When the overall market contribution is considered, the conventional devices segment accounts for 57.6% of the total market.
The market holds the highest numbers in the North American region, followed by Asia-Pacific. The U.S. leads the table by contributing 33.2% of the total market in 2020. It is expected that by the end of the forecast period 2021-2031, the Asia-Pacific region will lead the market in the region-based segmentation.

Key Topics Covered:

1 Scope of Research Study

2 Research Methodology

3 Industry Outlook

4 Competitive Assessment

5 Market Dynamics
5.1 Impact Analysis
5.2 Market Drivers
5.2.1 Increasing Prevalence of Cardiovascular Diseases (CVDs) and other Heart-Related Diseases
5.2.2 Growing Demands for Point-of-Care Diagnostic Systems
5.2.3 Rising End-User Preference for Non-Invasive Diagnostic Technologies over Invasive Technologies
5.3 Market Restraints
5.3.1 Longer Turnaround Time (TAT)
5.3.2 Incomplete and False Diagnosis
5.4 Market Trends
5.4.1 Rise in Demand for Holter Monitors
5.4.2 Development of Insertable Cardiac Monitors
5.5 Market Opportunities
5.5.1 Growing Market Preference for Multimodal Diagnostic Imaging Systems
5.5.2 Implementation of ECG in Hybrid Operating Rooms

6 Global Electrocardiographs Market
6.1 Global Market Outlook
6.2 Key Findings
6.3 Assumptions and Limitations

7 Global Electrocardiographs Market (by Product Type)
7.1 Overview
7.2 Market Size and Forecast
7.2.1 Conventional Devices
7.2.1.1 Resting ECG Devices
7.2.1.2 Stress ECG Devices
7.2.2 Emerging Devices
7.2.2.1 Implantable Loop Recorders
7.2.2.2 Mobile Cardiac Telemetry
7.2.2.2.1.1 Lead-Based Mobile Cardiac Telemetry
7.2.2.2.2 Patch-Based Mobile Cardiac Telemetry
7.2.2.3 Holter Monitors
7.2.2.4 Cardiac Event Monitors

8 Global Electrocardiographs Market (by End User)
8.1 Overview
8.1.1 Market Size and Forecast
8.1.1.1 Hospitals and Clinics
8.1.1.2 Home Care Settings and Ambulatory Surgical Centers
8.1.1.3 Others

9 Global Electrocardiographs Market (by Region)

10 Company Profiles
10.1 Overview
10.2 Abbott Laboratories
10.2.1 Company Outlook
10.2.2 Company Description
10.2.3 Financials
10.2.4 SWOT Analysis
10.3 Biotricity, Inc.
10.3.1 Company Outlook
10.3.2 Company Description
10.3.3 Financials
10.3.4 SWOT Analysis
10.4 BIOTRONIK SE & Co. KG
10.4.1 Company Overview
10.4.2 Company Description
10.4.3 SWOT Analysis
10.5 Boston Scientific Corporation
10.5.1 Company Outlook
10.5.2 Company Description
10.5.3 Financials
10.5.4 SWOT Analysis
10.6 CardioComm Solutions, Inc.
10.6.1 Company Outlook
10.6.2 Company Description
10.6.3 Financials
10.6.4 SWOT Analysis
10.7 Cardioline SpA
10.7.1 Company Overview
10.7.2 Company Description
10.7.3 SWOT Analysis
10.8 Fukuda Denshi Co., Ltd.
10.8.1 Company Outlook
10.8.2 Company Description
10.8.3 Financials
10.8.4 SWOT Analysis
10.9 General Electric Company
10.9.1 Company Outlook
10.9.2 Company Description
10.9.3 Financials
10.9.4 SWOT Analysis
10.10 Hill-Rom Holdings, Inc.
10.10.1 Company Outlook
10.10.2 Company Description
10.10.3 Financials
10.10.4 SWOT Analysis
10.11 iRhythm Technologies, Inc.
10.11.1 Company Outlook
10.11.2 Company Description
10.11.3 Financials
10.11.4 SWOT Analysis
10.12 Koninklijke Philips N.V.
10.12.1 Company Outlook
10.12.2 Company Description
10.12.3 Financials
10.12.4 SWOT Analysis
10.13 Medtronic plc
10.13.1 Company Outlook
10.13.2 Company Description
10.13.3 Financials
10.13.4 SWOT Analysis
10.14 Nihon Kohden Corporation
10.14.1 Company Outlook
10.14.2 Company Description
10.14.3 Financials
10.14.4 SWOT Analysis
10.15 OSI Systems, Inc.
10.15.1 Company Outlook
10.15.2 Company Description
10.15.3 Financials
10.15.4 SWOT Analysis
10.16 Zoll Medical Corporation (Asahi Kasei Corporation)
10.16.1 Company Outlook
10.16.2 Company Description
10.16.3 Financials
10.16.4 SWOT Analysis